ReviewCellular oncology (Dordrecht, Netherlands)2023
Circulating tumour cell isolation, analysis and clinical application.
Review in Cellular oncology (Dordrecht, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.Cancer medicine · 2025Pooled it
- Applications of circulating tumor cells in esophageal cancer detection and treatment.Discover oncology · 2026Review
- Adherent-to-suspension transition modulates circulating tumor cell dynamics and metastatic potential in melanoma.Molecules and cells · 2026Article
- Advances in isolation and detection technologies and immunotherapy applications of circulating tumor cells (Review).Oncology reports · 2026Review
- Circulating Tumor Cells: Emerging Frontiers in Cancer Technology.Expert reviews in molecular medicine · 2026Review
- Circadian rhythms as a modulator of gut microbiota-tumor microenvironment crosstalk.Cellular and molecular life sciences : CMLS · 2025Review
- Potentialities and challenges of liquid biopsy in clinical cancer management.Biomarkers in medicine · 2025Review
- Machine Learning-Enabled Non-Invasive Screening of Tumor-Associated Circulating Transcripts for Early Detection of Colorectal Cancer.International journal of molecular sciences · 2025Article
- A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells.The journal of liquid biopsy · 2024Review
- Liquid Biopsy in the Clinical Management of Cancers.International journal of molecular sciences · 2024Review
- Prognostic evaluation of a multi-target magnetic bead-enriched circulating tumor cell-enriched identification system for colorectal cancer.Journal of gastrointestinal oncology · 2024Article
- Advances in circulating tumor cells for early detection, prognosis and metastasis reduction in lung cancer.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating tumour cells (CTCs) are cancer cells that circulate in the bloodstream after being shed from solid tumours. They can lead to tumour recurrence and metastasis. CTCs play a significant role as biomarkers for early diagnosis, therapy response monitoring, and prognostication. However, CTCs are rare and heterogeneous, with usually only a single-digit number in one millilitre of blood. Additionally, a circadian rhythm is involved in the release of CTCs into the peripheral circulation. Due to these biological properties, higher demands are placed on the isolation of CTCs, and current capture methods struggle to enrich all CTCs present in blood. As yet, these limitations have hampered the clinical application of CTCs.
conclusionsIn this review, we focus on the biological properties and clinical applications of CTCs and current CTC enrichment and isolation methods. Combined enrichment methods based on physical and biological properties are considered instrumental for the development of highly specific and sensitive CTC capture methods. The utilization of CTCs in conjunction with other liquid biopsy components (such as ctDNA) may yield more clinically useful information and the circadian rhythmicity of CTC release may change the way to evaluate and treat patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.